The change applies to all monovalent forms of vaccine Comirnaty produced on and after Jan. 9 2023. The decision is said to be based on new studies by Pfizer.
The expansion was approved, Anvisa stated, after studies were unveiled by laboratories indicating the safety and efficiency of the vaccine for this group. The research was carried out overseas and assessed by the Brazilian watchdog.